Interleukin-17A Antagonists

Interleukin-17A Antagonist

Spondylitis, Ankylosing

Arthritis, Psoriatic

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11     DESCRIPTION</h1>Secukinumab, a recombinant human monoclonal IgG1/κ antibody, is an interleukin-17A antagonist. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.COSENTYX Injection for Subcutaneous UseCOSENTYX injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use. COSENTYX injection is supplied in a single-dose 300 mg/2 mL UnoReady pen with a 27-gauge fixed ½-inch needle, a single-dose 150 mg/mL Sensoready pen with a 27-gauge fixed ½-inch needle, or a single-dose prefilled syringe (300 mg/2 mL, 150 mg/mL, 75 mg/0.5 mL) with a 27-gauge fixed ½-inch needle. The removable cap of the COSENTYX 150 mg/mL Sensoready pen or 1 mL and 0.5 mL prefilled syringes contains natural rubber latex.Each COSENTYX 300 mg/2 mL UnoReady pen or 300 mg/2 mL prefilled syringe contains 300 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (6.206 mg), L-methionine (1.492 mg), polysorbate 80 (0.4 mg), trehalose dihydrate (151.34 mg), and Sterile Water for Injection, USP, at pH of 5.8.Each COSENTYX 150 mg/mL Sensoready pen or 150 mg/mL prefilled syringe contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.Each COSENTYX 75 mg/0.5 mL prefilled syringe contains 75 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (1.552 mg), L-methionine (0.373 mg), polysorbate 80 (0.1 mg), trehalose dihydrate (37.83 mg), and Sterile Water for Injection, USP, at pH of 5.8.COSENTYX Injection for Intravenous UseCOSENTYX solution is supplied as a sterile, preservative free, clear to opalescent, colorless to slightly yellowish solution in single-dose vials for intravenous infusion after dilution.Each COSENTYX vial contains 125 mg of secukinumab formulated in: L-histidine (5.67 mg), L-histidine hydrochloride monohydrate (13.3 mg), L-methionine (3.73 mg), polysorbate 80 (1 mg), trehalose dihydrate (426 mg), and Sterile Water for Injection, USP, at pH of 5.8.</section>

COSENTYX

secukinumab

1 ML secukinumab 150 MG/ML Prefilled Syringe

Cosentyx

1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

1 ML secukinumab 150 MG/ML Auto-Injector

1 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]

0.5 ML secukinumab 150 MG/ML Prefilled Syringe

0.5 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

2 ML secukinumab 150 MG/ML Auto-Injector

2 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]

5 ML secukinumab 25 MG/ML Injection

5 ML secukinumab 25 MG/ML Injection [Cosentyx]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.

Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis. 


Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form 

Reimbursement Information 

Billing & Coding Guide 

Consentyx Connect Start Form 

Cosentyx Connect Start Form - Spanish

Coverage Authorization Request

Coverage Authorization Appeals

Medical Exception Request Letter 

Enroll in Patient Savings Program 

Enroll in Bridge Program 

Cosentyx Patient Assistance Program Income Requirements 

Novartis Patient Assistance Foundation Application - English

Novartis Patient Assitance Foundation Application - Spanish 

Cosentyx Connect Support Program

Sharps Container 

About Cosentyx: Plaque Psoriasis 

FAQs: Plaque Psoriasis

Patient Stories: Plaque Psoriasis 

Twill Care App: Plaque Psoriasis

Taking Cosentyx: Plaque Psoriasis

Side Effects: Plaque Psoriasis 

About Cosentyx: Psoriatic Arthritis 

FAQs: Psoriatic Arthritis 

Patient Stories: Psoriatic Arthritis 

Patient Resources: Psoriatic Arthritis 

Taking Cosentyx: Psoriatic Arthritis 

About Cosentyx: Ankylosing Spondylitis

Patient Stories: Ankylosing Spondylitis

FAQs: Ankylosing Spondylitis 

Taking Cosentyx: Ankylosing Spondylitis 

About Cosentyx: nr-axSpA

FAQs: nr-axSpA 

Taking Cosentyx: nr-axSpA

About Cosentyx: Pediatric Psoriasis 

About Cosentyx: ERA & JPsA

Instructions For Use (75mg Pre-filled Syringe): All Indications 

Instructions For Use (150 mg Pre-filled Syringe): All Indications 

Instructions For Use (150mg Sensoready Pen): All Indications 

Instructions For Use (Video - 150 mg Sensoready Pen): All Indications 

Side Effects: Psoriatic Arthritis 

Patient Resources: Ankylosing Spondylitis

Side Effects: Ankylosing Spondylitis

Side Effects: nr-axSpa